Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $132.9 million.

  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) rose 690.47% to $132.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 690.47%. This contributed to the annual value of $121.0 million for FY2024, which is 7452.82% up from last year.
  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) amounted to $132.9 million in Q3 2025, which was up 690.47% from $127.0 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $132.9 million for Q3 2025, and its period low was $47.3 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $61.4 million (2023), whereas its average is $80.5 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) skyrocketed by 284.33% in 2022 and then skyrocketed by 10137.34% in 2024.
  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $49.4 million in 2021, then grew by 11.39% to $55.0 million in 2022, then increased by 25.94% to $69.3 million in 2023, then surged by 74.53% to $121.0 million in 2024, then grew by 9.86% to $132.9 million in 2025.
  • Its last three reported values are $132.9 million in Q3 2025, $127.0 million for Q2 2025, and $126.0 million during Q1 2025.